Striving to achieve pharmacoequity, or the goal of ensuring that all patients have equitable access to treatment, in ERBB2-positive breast cancer must be a priority.15 Furthermore, it is crucial to elucidate whether existing disparities may be associated with delayed adoption or long-term access gaps among racially and ethnically minoritized groups. This evidence concerns the gene ERBB2 and breast carcinoma.